213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Loading...
Date
Authors
Sathekge, Mike Machaba
Knoesen, Otto
Meckel, Marian
Modiselle, Moshe
Vorster, Mariza
Marx, Sebastian
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Prostate-specific membrane antigen radioligand therapy
(PSMA-RLT) with 177Lu-PSMA holds great promise as a
safe treatment option in patients with metastasized
castration-resistant prostate cancer (mCRPC) with appropriate
selection. This approach, together with 68Ga-PSMA PET/CT, is an excellent example of theranostic
nuclear medicine. However, more structured data have
recently shown that despite a marked response to PSMARLT,
some patients are refractory to 177Lu-radioligand
therapy. Fortunately recent studies have demonstrated
that targeted α-radiation therapy with 225Ac-PSMA can
significantly benefit mCRPC patients. Similarly, 213Bi-DOTATOC may be able to break the radioresistance to β-emitters while simultaneously reducing haematological
toxicity in patients with diffuse red marrow infiltration
by neuroendocrine tumour.
Description
Keywords
177Lu-PSMA, Treatment, Patients, Prostate-specific membrane antigen radioligand therapy (PSMA-RLT), Metastasized castration-resistant prostate cancer (mCRPC)
Sustainable Development Goals
Citation
Sathekge, M., Knoesen, O., Meckel, M. et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 1099-1100. https://doi.org/10.1007/s00259-017-3657-9.